These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11710296)

  • 21. Immune boosters. Murabutide--debut of a new immune booster?
    TreatmentUpdate; 2003; 15(4):3. PubMed ID: 17216851
    [No Abstract]   [Full Text] [Related]  

  • 22. Development of the cytokine inducer romurtide: experimental studies and clinical application.
    Azuma I
    Trends Pharmacol Sci; 1992 Dec; 13(12):425-8. PubMed ID: 1293866
    [No Abstract]   [Full Text] [Related]  

  • 23. [Likopid in complex treatment of oral dysbiosis].
    Rabinovich OF; Rabinovich IM; Abramova ES
    Stomatologiia (Mosk); 2013; 92(1):40-2. PubMed ID: 23528400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The effect of the immunomodulator glucosaminylmuramyl dipeptide on hematopoiesis in mice with experimental cytopenia].
    Andrianova IE; Filimonova GI; Andronova TM
    Radiobiologiia; 1992; 32(4):566-70. PubMed ID: 1410295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunodulator murabutide.
    Bahr GM
    J Antimicrob Chemother; 2003 Jan; 51(1):5-8. PubMed ID: 12493780
    [No Abstract]   [Full Text] [Related]  

  • 26. [Enhancement of resistance to microbial infection].
    Tamura M; Mameoka Y; Tsubura E
    Nihon Kyobu Shikkan Gakkai Zasshi; 1985 Feb; 23(2):171-5. PubMed ID: 3839543
    [No Abstract]   [Full Text] [Related]  

  • 27. [The immunostimulating activity of muramyl dipeptide and its derivatives].
    Karsonova MI; Andronova TM; Pinegin BV; Khaitov RM
    Zh Mikrobiol Epidemiol Immunobiol; 1999; (3):104-10. PubMed ID: 10852007
    [No Abstract]   [Full Text] [Related]  

  • 28. Biological response modifiers.
    Clark JW
    Cancer Chemother Biol Response Modif; 1991; 12():193-212. PubMed ID: 1931443
    [No Abstract]   [Full Text] [Related]  

  • 29. [Current aspects of diagnosis and treatment of atopic diseases complicated by secondary immunodeficiency].
    Mikheeva GN; Khaitov RM
    Ter Arkh; 1998; 70(4):54-60. PubMed ID: 9612905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative characteristic of the treatment efficacy in patients with often recurrent acute respiratory infections complicated with immunodeficiency treated with likopid].
    Chop'iak VV; Pot'omkina HO
    Lik Sprava; 2013 Mar; (2):106-17. PubMed ID: 24605620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Muramyldipeptide - based compounds in current medicine: focus on glucosaminylmuramyl dipeptide].
    Ushkalova EA; Zyryanov SK; Zatolochina KE
    Ter Arkh; 2019 Dec; 91(12):122-127. PubMed ID: 32598599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Synthesis and protective anti-infective action of anomeric lipophilic glycosides of N-acetylmuramyl-L-alanyl-D-isoglutamine].
    Zemliakov AE; Tsikalova VN; Tsikalov VV; Chirva VIa; Mulik EL; Kaliuzhin OV
    Bioorg Khim; 2006; 32(4):424-31. PubMed ID: 16909867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic and prophylactic effects of romurtide against experimental animal infections.
    Niki Y; Tatara O
    Adv Exp Med Biol; 1992; 319():185-91. PubMed ID: 1414593
    [No Abstract]   [Full Text] [Related]  

  • 34. [Characteristics and clinical use of immunostimulants].
    Shirinskiĭ VS; Zhuk EA
    Ter Arkh; 1990; 62(12):125-32. PubMed ID: 1707558
    [No Abstract]   [Full Text] [Related]  

  • 35. A note on the failure of CGP 19835 A (MTP-PE) to influence the course of influenza A2 infection in human volunteers.
    Higgins PG; Barrow GI; Galbraith AW; Frost H; Tyrrell DA
    Antiviral Res; 1989 Aug; 12(1):49-52. PubMed ID: 2596839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunostimulants--therapeutic aspects].
    Diezel W; Volk HD; Daniel V; Gruner S; Sönnichsen N
    Arch Geschwulstforsch; 1989; 59(1):45-51. PubMed ID: 2493778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New approaches for control of infections using synthetic or semi-synthetic constructs containing MDP.
    Chedid L; Audibert F
    Springer Semin Immunopathol; 1985; 8(4):401-12. PubMed ID: 4089758
    [No Abstract]   [Full Text] [Related]  

  • 38. Approaches to cancer therapy using biological response modifiers.
    MacEwen EG
    Vet Clin North Am Small Anim Pract; 1985 May; 15(3):667-88. PubMed ID: 2409659
    [No Abstract]   [Full Text] [Related]  

  • 39. [The influence of type MDP immunomodulators on secretion and activity of cytokines].
    Dzierzbicka K; Gozdowska M; Kołodziejczyk AM
    Postepy Biochem; 1998; 44(3):216-9. PubMed ID: 10022040
    [No Abstract]   [Full Text] [Related]  

  • 40. Restorative effect of MDP-Lys (L18) on leukopenia of cancer patient treated with radiotherapy.
    Okawa T; Kikuchi Y; Watarai J; Dokiya T; Tanaka T; Saito Y; Hirokawa Y; Takegawa Y; Hata K
    Nihon Igaku Hoshasen Gakkai Zasshi; 1988 Apr; 48(4):514-22. PubMed ID: 3231516
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.